In the two-year study of 350 subjects who had taken two previous cancer treatments, Aveo Oncology's renal cell carcinoma treatment tivozanib was linked to a lower risk of death than the current standard of care.

source https://finance.yahoo.com/m/8d45bdab-b478-34db-b82b-888a6c71b4f6/aveo-ceo-says-new-data-eases.html?.tsrc=rss